Chronic venous disorders: pharmacological and clinical aspects of micronized purified flavonoid fraction

Chronic venous disorders: pharmacological and clinical aspects of micronized purified flavonoid fraction Arnaud MAGGIOLI 50 rue Carnot 92284 Suresnes, France Abstract Micronized purified flavonoid fraction (MPFF) is a flavonoid-based venoactive drug that is more potent than pure diosmin due to the presence of additional flavonoids, such as hesperidin, diosmetin, linarin, and isorhoifolin. In addition, the dissolution and absorption rates of MPFF increase due to the micronization of its active ingredients. The micronization process improves exposure to MPFF– derived metabolites that are responsible for its pharmacological activity. The positive impact of micronization on the pharmacological activity of purified flavonoid fraction has…

Full text

MPFF and the protection of venous valves

MPFF and the protection of venous valves Luigi Pascarella Iowa City, USA Abstract Increased venous pressure underlies all the clinical manifestations of chronic venous disorders. Venous hypertension is the result of incompetent venous valves in the superficial veins for most patients. A strong link between venous hypertension, valve failure and venous inflammation has been evoked through pharmacological studies and confirmed in a variety of animal models. A cascade of inflammatory reactions results in adverse changes in the venous valve and venous wall that eventually produce venous hypertension. Symptoms, telangiectasias, varicose veins, and eventually venous leg ulcers appear to be a…

Full text

Conservative treatment of chronic venous disease: the Italian experience

Giovanni B. AGUS Section of Vascular Surgery and Angiology, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. ABSTRACT Chronic venous disease (CVD) is a highly prevalent clinical condition with substantial epidemiological implications and socioeconomic repercussions. CVD is a worldwide problem and does not only affect patients in Western countries. The consequences of its high prevalence, diagnosis and therapy costs, significant worker absenteeism, and its impact on patients’ quality of life are well known. Pharmacotherapy for CVD, solely represented by venoactive drugs, has seen great developments over the last 40 years. Venoactive drugs are widely used in…

Full text

Efficacy of a 6-month treatment with MPFF at a dose of 500 mg* in patients with venous edema (Efficacy of MPFF at a dose of 500 mg* in Edema Treatment. EDET)

Zuzana NAVRÁTILOVÁ1 and the EDET study group2 1 Ambulance dermatologické angiologie, Brno, Czech Republic. 2 Andrš P. (Prost ějov), Diamantová D. (Olomouc), Felixová V. (Kralupy nad Vltavou), Flášarová V. (Brno), Hubáčková N. (St říbro), Jašková E. (Opava), Ješinová M (Teplice), Kazinota V. (Břeclav), Komárková K. (Praha), Komrsová H. (Praha), Koťátková D. (Pardubice), Krátký P. (Jablonec nad Nisou), Kreml M. (Kyjov), Kruková M. (Praha), Lánová M. (Ústí nad Orlicí), Michálková M. (Ostrava), Navrátilová Z. (Brno), Neumannová R. (Chomutov), Pacejka M. (Zlín), Pelikánová D. (Prostějov), Procházka P. (Kladno), Scheetyová R. (Olomouc), Šmejkalová D. (České Bud ějovice), Špale Z. (Sedl čany), Švestková S….

Full text

Chronic pelvic pain associated with pelvic congestion syndrome and the benefit of MPFF at a dose of 500 mg: a review*

Feza BURAK1 Tonguc GUNDUZ2 Mehmet SIMSEK2 Omur TASKIN1,2 Departments of Obstetrics and Gynecology Ìnonu University 1, Malatya and Akdeniz University 2, Antalya School of Medicine * This review is based on the following publication: 1) Taskin O, Uryan I I, Buhur A, et al. The Effects of MPFF on Pelvic Pain in Women with Taylor Syndrome. J Am Assoc Gynecol Laparosc. 1996;3(4, Supplement):S49, and 2) Simsek M, Burak F, Taskin O. Effects of micronized purified flavonoid fraction on pelvic pain in women with laparoscopically diagnosed pelvic congestion syndrome: a randomized crossover trial. Clin Exp Obstet Gynecol. 2007;34(2):96-98. SUMMARY Chronic pelvic…

Full text

Pharmacological treatment of chronic venous disorders

Michel PERRIN1 and George GEROULAKOS2 1. Vascular Surgeon, Chassieu, France 2. Consultant Vascular Surgeon, Ealing and Charing Cross Hospital, Senior Lecturer, Department of Vascular Surgery, Imperial College of Science Technology and Medicine, London, UK The term chronic venous disorder (CVD) is used to denote all abnormal clinical changes that result from venous disease of the lower extremities, and that have a chronic course.1 According to this definition, CVD includes patients who present with so-called symptoms and/or signs of venous disease that characterize each class of CVD in the Clinical, Etiological, Anatomical, Pathophysiological (CEAP) classification,2 from class C0s to class C6….

Full text

Stripping of the great saphenous vein under micronized purified flavonoid fraction (MPFF) protection (results of the Russian multicenter controlled trial DEFANCE)

Victor S. SAVELJEV2 Anatoly V. POKROVSKY1 Alexander I. KIRIENKO2 Vadim YU. BOGACHEV2 Igor A. ZOLOTUKHIN2 Sergey V. SAPELKIN1 SUMMARY This paper presents the results of the DEFANCE study (Daflon 500 mg* – assEssment of eFficacy ANd safety for Combined phlEbectomy study). The aim of the study was to compare the intensity of postoperative pain, the size of postoperative hematoma, and quality-of-life score between two groups of patients: • a MPFF at a dose of 500 mg group: patients who underwent stripping of the great saphenous vein (GSV) and were treated with MPFF at a dose of 500 mg 14 days…

Full text